CEO Blog, page-3

"We propose to run 2 clinical studies, each providing a two-shot approach. The first shot has nothing to do with an abscopal response. We simply will be testing whether we can radio-sensitise the 1-2 tumours that are exposed to radiotherapy. In this case we will be using a low dose of radiation that would not be expected to deliver anything more than partial shrinkage. We are expecting complete remission of those exposed tumours. If this is all we achieve, then we will have achieved something highly significant and highly relevant in the field of cancer management." (GK CEO Blog Posted on March 6th, 2017)

https://www.noxopharm.com/site/Blog...ood-reason-to-be-excited-by-the-word-abscopal